Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Negative T790M Mutation and Met Amplification 1C-Met Exon 14 Mutation 1Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors 1

Interventions

glumetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Negative T790M Mutation and Met Amplification × glumetinib × Clear all
NCT04338243 2020-04-08

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Haihe Biopharma Co., Ltd.

Phase 1/2 Unknown
70 enrolled

Negative T790M Mutation and Met Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡